HUP0204439A2 - Eljárás mucinok szintézisének fokozására vagy fenntartására - Google Patents

Eljárás mucinok szintézisének fokozására vagy fenntartására

Info

Publication number
HUP0204439A2
HUP0204439A2 HU0204439A HUP0204439A HUP0204439A2 HU P0204439 A2 HUP0204439 A2 HU P0204439A2 HU 0204439 A HU0204439 A HU 0204439A HU P0204439 A HUP0204439 A HU P0204439A HU P0204439 A2 HUP0204439 A2 HU P0204439A2
Authority
HU
Hungary
Prior art keywords
improving
maintaining
synthesis
mucins
patient
Prior art date
Application number
HU0204439A
Other languages
English (en)
Inventor
Olivier Ballevre
Denis Breuille
Paul-André Finot
Original Assignee
Société des Produits Nestlé S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204439(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/774,814 external-priority patent/US6833350B2/en
Application filed by Société des Produits Nestlé S. A. filed Critical Société des Produits Nestlé S. A.
Publication of HUP0204439A2 publication Critical patent/HUP0204439A2/hu
Publication of HUP0204439A3 publication Critical patent/HUP0204439A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány mucinok szintézisének fokozására vagy javítására ésfenntartására szolgáló módszerekre vonatkozik, különösen a gyomor-bélrendszerben és a tüdőben. A találmány továbbá betegben mucinokszintézisének fokozására vagy javítására és fenntartására szolgálómódszerekre vonatkozik, amelynek során a betegnek olyantáplálékkompozíciót adagolnak, amely treonin terápiásan hatékonymennyiségét tartalmazza. Ó
HU0204439A 2000-02-04 2001-01-31 A method for maintaining or improving the synthesis of mucins HUP0204439A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49890500A 2000-02-04 2000-02-04
US09/774,814 US6833350B2 (en) 2000-02-04 2001-01-30 Method for maintaining or improving the synthesis of mucins
PCT/EP2001/001013 WO2001056405A2 (en) 2000-02-04 2001-01-31 A method for maintaining or improving the synthesis of mucins

Publications (2)

Publication Number Publication Date
HUP0204439A2 true HUP0204439A2 (hu) 2003-04-28
HUP0204439A3 HUP0204439A3 (en) 2004-12-28

Family

ID=27052980

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204439A HUP0204439A3 (en) 2000-02-04 2001-01-31 A method for maintaining or improving the synthesis of mucins

Country Status (22)

Country Link
EP (1) EP1255452B2 (hu)
JP (1) JP2003533436A (hu)
CN (1) CN1434681B (hu)
AT (1) ATE323422T1 (hu)
AU (1) AU784137B2 (hu)
BG (1) BG106967A (hu)
BR (1) BRPI0108096B1 (hu)
CA (1) CA2399063C (hu)
CZ (1) CZ20022978A3 (hu)
DE (1) DE60118888T3 (hu)
DZ (1) DZ3298A1 (hu)
ES (1) ES2261383T5 (hu)
HR (1) HRP20020647A2 (hu)
HU (1) HUP0204439A3 (hu)
IL (1) IL150977A (hu)
MA (1) MA25656A1 (hu)
MX (1) MXPA02007491A (hu)
NO (1) NO20023640L (hu)
NZ (1) NZ520605A (hu)
PL (1) PL357078A1 (hu)
SK (1) SK11212002A3 (hu)
WO (1) WO2001056405A2 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1638418T3 (da) 2003-06-23 2012-09-17 Nestec Sa Aminosyretilsætning til et sundt mikrobiota-økosystem
JPWO2007004613A1 (ja) * 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
EP2340724A3 (en) * 2006-01-09 2012-02-29 Nestec S.A. Treatment of stressed patients
WO2012133198A1 (ja) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
WO2013016111A1 (en) 2011-07-22 2013-01-31 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP3167895A1 (en) * 2015-11-10 2017-05-17 University College Dublin A dietary supplement comprising beta-glucan and casein hydrolysate for improving health and growth performance in a mammal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459620B1 (fr) * 1979-06-26 1983-08-05 Agronomique Inst Nat Rech Hydrolisat enzymatique total de proteines de lactoserum, obtention et application
US5162373A (en) * 1986-01-17 1992-11-10 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
JP3007694B2 (ja) * 1990-12-14 2000-02-07 雪印乳業株式会社 胃潰瘍予防または治療のための医薬及び飲食品
AU679020B2 (en) * 1992-12-23 1997-06-19 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
FR2711529B1 (fr) * 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
JPH07267855A (ja) * 1994-03-30 1995-10-17 Taiho Yakuhin Kogyo Kk グルタミン産生剤
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5670157A (en) * 1995-12-11 1997-09-23 Nestec Ltd. Method for reducing and controlling immunoglobulin concentrations
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
CA2300076A1 (en) * 1997-09-16 1999-03-25 Societe Des Produits Nestle S.A. Organ specific nutrition
WO1999067373A2 (en) * 1998-06-24 1999-12-29 Boyce Thompson Institute For Plant Research, Inc. Invertebrate intestinal mucins, cdnas, antibodies and their use
EP1034704A1 (en) * 1999-03-12 2000-09-13 Societe Des Produits Nestle S.A. Nutritional composition intended for specific gastro-intestinal maturation in premature mammals
CA2387907A1 (en) * 1999-10-22 2001-05-03 The Board Of Regents Of The University Of Nebraska Serum amyloid a isoform from colostrum

Also Published As

Publication number Publication date
EP1255452B2 (en) 2010-03-03
CZ20022978A3 (cs) 2003-02-12
BRPI0108096B1 (pt) 2017-05-09
ES2261383T3 (es) 2010-06-14
AU4056401A (en) 2001-08-14
CN1434681B (zh) 2010-12-08
NO20023640L (no) 2002-09-19
PL357078A1 (en) 2004-07-12
JP2003533436A (ja) 2003-11-11
CA2399063C (en) 2014-01-28
DZ3298A1 (fr) 2001-08-09
CN1434681A (zh) 2003-08-06
SK11212002A3 (sk) 2003-01-09
IL150977A0 (en) 2003-02-12
NZ520605A (en) 2004-06-25
BG106967A (bg) 2003-04-30
IL150977A (en) 2005-09-25
MXPA02007491A (es) 2002-12-13
DE60118888T2 (de) 2007-01-18
ATE323422T1 (de) 2006-05-15
MA25656A1 (fr) 2002-12-31
NO20023640D0 (no) 2002-07-31
DE60118888T3 (de) 2010-09-23
HRP20020647A2 (en) 2004-12-31
CA2399063A1 (en) 2001-08-09
ES2261383T5 (es) 2010-06-18
DE60118888D1 (de) 2006-05-24
HUP0204439A3 (en) 2004-12-28
WO2001056405A3 (en) 2002-01-24
EP1255452B1 (en) 2006-04-19
AU784137B2 (en) 2006-02-09
BR0108096A (pt) 2002-10-29
EP1255452A2 (en) 2002-11-13
WO2001056405A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1539228A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
WO2002070510A3 (de) Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
GB0223040D0 (en) Therapeutic compounds
TNSN04136A1 (en) Aza-arylpiperazines
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
HUP0301819A2 (hu) Illóolajok alkalmazása Helicobacter-szerű organizmusok által előidézett gyomor- és bélrendszeri fertőzések leküzdésére
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
HUP0204439A2 (hu) Eljárás mucinok szintézisének fokozására vagy fenntartására
EP1578373A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
AP2003002753A0 (en) Use of salmeterol and fluticasone propionate combination
NO20082672L (no) Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
EA200100515A2 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
EP1562587A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM
MXPA03010921A (es) Uso de acetil l-carnitina en asociacion con biotina para tratamiento der pacientes con diabetes mellitus resistente a insulina tipo 2.
DE60336063D1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren